These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Immunomodulation by proteases. Potential for treating diabetes mellitus?]. Martin S Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 9():S319-22. PubMed ID: 19085662 [No Abstract] [Full Text] [Related]
24. [Perspectives of immunomodulation with peptides in treatment of atopic diseases]. Kruszewski J Pneumonol Alergol Pol; 1992; 60(7-8):72-4. PubMed ID: 1493524 [No Abstract] [Full Text] [Related]
25. [Will type I diabetes mellitus be treated with immunosuppressive drugs in the future?]. Diem P Ther Umsch; 1993 Feb; 50(2):114-8. PubMed ID: 8456415 [TBL] [Abstract][Full Text] [Related]
27. Recent concepts of pathogenesis and treatment of type I diabetes. Ann Clin Res; 1984; 16(2):51-135. PubMed ID: 6380387 [No Abstract] [Full Text] [Related]
28. Autoantibodies in diabetes mellitus: current utility and perspectives. Isermann B; Ritzel R; Zorn M; Schilling T; Nawroth PP Exp Clin Endocrinol Diabetes; 2007 Sep; 115(8):483-90. PubMed ID: 17853330 [TBL] [Abstract][Full Text] [Related]
29. [Functional deficiency of the Fc(IgG) receptor of peripheral blood monocytes in uncompensated diabetes mellitus]. Gómez Rodríguez F; Ruiz Alcantarilla P; Zamora Madaria E Rev Clin Esp; 1986 Nov; 179(7):343-6. PubMed ID: 3797746 [No Abstract] [Full Text] [Related]
30. [Topinambur concentrate in the treatment of patients with insulin-dependent diabetes mellitus]. Zhuk EA; Zelenkov VN Vopr Pitan; 1997; (6):34-6. PubMed ID: 9542000 [TBL] [Abstract][Full Text] [Related]
31. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy. Tian B; Hao J; Zhang Y; Tian L; Yi H; O'Brien TD; Sutherland DE; Hering BJ; Guo Z Transplantation; 2009 Jan; 87(2):198-206. PubMed ID: 19155973 [TBL] [Abstract][Full Text] [Related]
32. [Complement (C3) receptor dependent monocyte recognition in uncompensated diabetes mellitus types I and II]. Gómez Rodríguez F; Ruiz Alcantarilla P; Zamora Madaria E Rev Clin Esp; 1986 Sep; 179(4):167-71. PubMed ID: 3532232 [No Abstract] [Full Text] [Related]
33. [Immunosuppression in juvenile diabetes mellitus? Critical viewpoint on the treatment with cyclosporin A with consideration of the differential etiology]. Teuber J; Usadel KH Fortschr Med; 1985 Jul; 103(27-28):707-13. PubMed ID: 4029865 [No Abstract] [Full Text] [Related]
34. Dosing and timing effects of anti-CD40L therapy: predictions from a mathematical model of type 1 diabetes. Gadkar KG; Shoda LK; Kreuwel HT; Ramanujan S; Zheng Y; Whiting CC; Young DL Ann N Y Acad Sci; 2007 Apr; 1103():63-8. PubMed ID: 17376835 [TBL] [Abstract][Full Text] [Related]
35. [Immunosuppression trials in type I diabetes]. Feutren G; Boitard C; Assan R; Bach JF Journ Annu Diabetol Hotel Dieu; 1987; ():147-69. PubMed ID: 3302472 [No Abstract] [Full Text] [Related]
36. Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage. Waldron-Lynch F; Herold KC Endocrinol Metab Clin North Am; 2009 Jun; 38(2):303-17, viii. PubMed ID: 19328413 [TBL] [Abstract][Full Text] [Related]
38. [Type 1 diabetes: the rediscovery of insulin]. Boitard C Journ Annu Diabetol Hotel Dieu; 2007; ():181-9. PubMed ID: 18610769 [No Abstract] [Full Text] [Related]
39. [Immunologic aspects of type I diabetes]. Fucíková T; Sterzl I Cas Lek Cesk; 1988 Mar; 127(13):390-3. PubMed ID: 3365740 [No Abstract] [Full Text] [Related]